Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2022 Earnings Call Transcript

And obviously, the markets have been pretty tough on all the companies in the biotech space. We’re certainly seeing the ultra-orphan neuro diseases for lack of a better being left behind. We’ve had a lot of inbound calls from companies who have broad portfolios and can’t find the resources to work in the ultra-orphan neuro space. So we do think there’ll be some opportunities for us over time. We’ve got to stay focused on our execution on our late stage programs, but I think we’d love to do more in the space. We all really enjoy it. Thanks for the question. Jay. Operator will go to the next question.

Operator: We have no further questions at this time. So I would turn the call back to Mr. Scott Braunstein for closing remarks.

Scott Braunstein: Well, thank you and thanks everyone for dialing in today. Thank you for all the questions. We really could not be more excited about where we stand today, early days of this ZTALMY launch and the progress we’re making on the clinical side as well as the expanded pipeline and now the extended cash runway. So we really appreciate all your support and your time today and look forward to seeing you live. Have a good day, everyone.

Operator: Ladies and gentlemen, this concludes today’s call. We thank you for your participation. You may now disconnect.